Overview
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
Status:
Completed
Completed
Trial end date:
2012-09-01
2012-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to examine the long-term safety of treating recurrent episodes of tinea pedis for 14 days for each recurrence and recurrent episodes of tinea corporis or tinea cruris for 7 days for each recurrence with Product 33525.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tinea Pharmaceuticals
Criteria
Inclusion Criteria:- Evidence of tinea cruris, tinea pedis, or tinea corporis. Additional criteria listed
in protocol
Exclusion Criteria:
- Pregnancy and allergies. Additional criteria listed in protocol